← Back to Calendar
Live Company Data
NMS
Updated
just now
· Data: FMP
Current Price
$27.77
+141.48%
+$16.27 today
Day: $27.50 – $29.27
52-Week Range
Current price is at 65% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Duchenne muscular dystrophy (DMD) cardiomyopathy
Key Notes
BLA Class 2 resubmission. PDUFA August 22, 2026. FDA lifted prior CRL and resumed review after Capricor submitted HOPE-3 clinical trial data and supporting documentation in March 2026. Deramiocel is a cardiosphere-derived cell therapy. Company expects to be eligible for a Priority Review Voucher (PRV) upon potential approval — PRV currently worth ~$100M+. DMD cardiomyopathy is the leading cause of death in DMD patients. Sub-$500M market cap binary event.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.